Dan Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dan Shi has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Bowen Lin
State Key Laboratory of Cardiovascular Diseases and Department of Cardiology (B.L., C.L., M.S., L.H., L.C., J.Y., D.S., Y.-H.C.), School of Medicine, Tongji University, Shanghai, China
6 shared publicationsLe Ni
Department of Cardiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
5 shared publicationsLingjie Hu
State Key Laboratory of Cardiovascular Diseases and Department of Cardiology (B.L., C.L., M.S., L.H., L.C., J.Y., D.S., Y.-H.C.), School of Medicine, Tongji University, Shanghai, China
5 shared publicationsJian Yang
Department of Cardiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
4 shared publicationsMeiting Shen
State Key Laboratory of Cardiovascular Diseases and Department of Cardiology (B.L., C.L., M.S., L.H., L.C., J.Y., D.S., Y.-H.C.), School of Medicine, Tongji University, Shanghai, China
4 shared publicationsCan Li
State Key Laboratory of Cardiovascular Diseases and Department of Cardiology (B.L., C.L., M.S., L.H., L.C., J.Y., D.S., Y.-H.C.), School of Medicine, Tongji University, Shanghai, China
3 shared publications
Latest Publications
- 17 March 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (11) , 845-862
CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy
BACKGROUND: Hypertrophic cardiomyopathy (HCM), the most common inherited cardiac disorder and a leading cause of sudden cardiac death in young adults, exhibits substantial genetic and clinical heterogeneity. Although sarcomere gene sequence variations account for a major proportion of HCM cases, nearly half of patients lack identifiable genetic defects, implying the involvement of undiscovered mechanisms that may converge on a common pathogenic pathway. However, a unified molecular basis underlying HCM pathogenesis remains undefined. METHODS: We conducted an integrated analysis of hypertrophied interventricular septum tissues from 269 patients with obstructive HCM undergoing surgical myectomy. Targeted sarcomere gene screening, bulk RNA sequencing, and weighted gene coexpression network analysis were used to identify candidate drivers of disease. Cross-species validation was performed using a Myh 6 R404Q/+ mouse model. Single-cell RNA sequencing delineated the cellular source of key factors, and biochemical assays and gain- and loss-of-function studies were used to assess their functional relevance. CRLF1 (cytokine receptor-like factor 1) emerged as a candidate mediator and was further evaluated in vitro and in vivo. RESULTS: CRLF1, predominantly secreted by activated cardiac fibroblasts, emerged as a key paracrine factor driving cardiomyocyte hypertrophy across patients with genetically heterogeneous HCM. CRLF1 levels were significantly elevated in hypertrophied myocardium and circulation. CRLF1 activated the LIFR (leukemia inhibitory factor receptor)–JAK1/2 (Janus kinase)–STAT3 (signal transducer and activator of transcription 3) signaling cascade to promote hypertrophy in both murine and human HCM models. Genetic ablation of Crlf1 in fibroblasts or pharmacological inhibition of its downstream pathway markedly attenuated disease phenotypes. CONCLUSIONS: Our findings uncover a common, nongenetic paracrine mechanism underlying HCM pathogenesis and establish CRLF1 as a promising universal therapeutic target for this heterogeneous disease.
- 17 March 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (11) , 845-862
CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy
BACKGROUND: Hypertrophic cardiomyopathy (HCM), the most common inherited cardiac disorder and a leading cause of sudden cardiac death in young adults, exhibits substantial genetic and clinical heterogeneity. Although sarcomere gene sequence variations account for a major proportion of HCM cases, nearly half of patients lack identifiable genetic defects, implying the involvement of undiscovered mechanisms that may converge on a common pathogenic pathway. However, a unified molecular basis underlying HCM pathogenesis remains undefined. METHODS: We conducted an integrated analysis of hypertrophied interventricular septum tissues from 269 patients with obstructive HCM undergoing surgical myectomy. Targeted sarcomere gene screening, bulk RNA sequencing, and weighted gene coexpression network analysis were used to identify candidate drivers of disease. Cross-species validation was performed using a Myh 6 R404Q/+ mouse model. Single-cell RNA sequencing delineated the cellular source of key factors, and biochemical assays and gain- and loss-of-function studies were used to assess their functional relevance. CRLF1 (cytokine receptor-like factor 1) emerged as a candidate mediator and was further evaluated in vitro and in vivo. RESULTS: CRLF1, predominantly secreted by activated cardiac fibroblasts, emerged as a key paracrine factor driving cardiomyocyte hypertrophy across patients with genetically heterogeneous HCM. CRLF1 levels were significantly elevated in hypertrophied myocardium and circulation. CRLF1 activated the LIFR (leukemia inhibitory factor receptor)–JAK1/2 (Janus kinase)–STAT3 (signal transducer and activator of transcription 3) signaling cascade to promote hypertrophy in both murine and human HCM models. Genetic ablation of Crlf1 in fibroblasts or pharmacological inhibition of its downstream pathway markedly attenuated disease phenotypes. CONCLUSIONS: Our findings uncover a common, nongenetic paracrine mechanism underlying HCM pathogenesis and establish CRLF1 as a promising universal therapeutic target for this heterogeneous disease.
- 13 February 2023
- Published by Springer Nature in Science China Life Sciences
- Vol. 66 (6) , 1264-1279
Histone modification landscape and the key significance of H3K27me3 in myocardial ischaemia/reperfusion injury
Histone modifications play crucial roles in the pathogenesis of myocardial ischaemia/reperfusion (I/R) injury. However, a genome-wide map of histone modifications and the underlying epigenetic signatures in myocardial I/R injury have not been established. Here, we integrated transcriptome and epigenome of histone modifications to characterize epigenetic signatures after I/R injury. Disease-specific histone mark alterations were mainly found in H3K27me3-, H3K27ac-, and H3K4me1-marked regions 24 and 48 h after I/R. Genes differentially modified by H3K27ac, H3K4me1 and H3K27me3 were involved in immune response, heart conduction or contraction, cytoskeleton, and angiogenesis. H3K27me3 and its methyltransferase polycomb repressor complex 2 (PRC2) were upregulated in myocardial tissues after I/R. Upon selective inhibition of EZH2 (the catalytic core of PRC2), the mice manifest improved cardiac function, enhanced angiogenesis, and reduced fibrosis. Further investigations confirmed that EZH2 inhibition regulated H3K27me3 modification of multiple pro-angiogenic genes and ultimately enhanced angiogenic properties in vivo and in vitro. This study delineates a landscape of histone modifications in myocardial I/R injury, and identifies H3K27me3 as a key epigenetic modifier in I/R process. The inhibition of H3K27me3 and its methyltransferase might be a potential strategy for myocardial I/R injury intervention.
- 13 February 2023
- Published by Springer Nature in Science China Life Sciences
- Vol. 66 (6) , 1264-1279
Histone modification landscape and the key significance of H3K27me3 in myocardial ischaemia/reperfusion injury
Histone modifications play crucial roles in the pathogenesis of myocardial ischaemia/reperfusion (I/R) injury. However, a genome-wide map of histone modifications and the underlying epigenetic signatures in myocardial I/R injury have not been established. Here, we integrated transcriptome and epigenome of histone modifications to characterize epigenetic signatures after I/R injury. Disease-specific histone mark alterations were mainly found in H3K27me3-, H3K27ac-, and H3K4me1-marked regions 24 and 48 h after I/R. Genes differentially modified by H3K27ac, H3K4me1 and H3K27me3 were involved in immune response, heart conduction or contraction, cytoskeleton, and angiogenesis. H3K27me3 and its methyltransferase polycomb repressor complex 2 (PRC2) were upregulated in myocardial tissues after I/R. Upon selective inhibition of EZH2 (the catalytic core of PRC2), the mice manifest improved cardiac function, enhanced angiogenesis, and reduced fibrosis. Further investigations confirmed that EZH2 inhibition regulated H3K27me3 modification of multiple pro-angiogenic genes and ultimately enhanced angiogenic properties in vivo and in vitro. This study delineates a landscape of histone modifications in myocardial I/R injury, and identifies H3K27me3 as a key epigenetic modifier in I/R process. The inhibition of H3K27me3 and its methyltransferase might be a potential strategy for myocardial I/R injury intervention.
- Open Access
- 23 December 2022
- Published by Springer Nature in Cell Death Discovery
- Vol. 8 (1) , 1-14
PKM2 deficiency exacerbates gram-negative sepsis-induced cardiomyopathy via disrupting cardiac calcium homeostasis
Sepsis is a life-threatening syndrome with multi-organ dysfunction in critical care medicine. With the occurrence of sepsis-induced cardiomyopathy (SIC), characterized by reduced ventricular contractility, the mortality of sepsis is boosted to 70–90%. Pyruvate kinase M2 (PKM2) functions in a variety of biological processes and diseases other than glycolysis, and has been documented as a cardioprotective factor in several heart diseases. It is currently unknown whether PKM2 influences the development of SIC. Here, we found that PKM2 was upregulated in cardiomyocytes treated with LPS both in vitro and in vivo. Pkm2 inhibition exacerbated the LPS-induced cardiac damage to neonatal rat cardiomyocytes (NRCMs). Furthermore, cardiomyocytes lacking PKM2 aggravated LPS-induced cardiomyopathy, including myocardial damage and impaired contractility, whereas PKM2 overexpression and activation mitigated SIC. Mechanism investigation revealed that PKM2 interacted with sarcoplasmic/endoplasmic reticulum calcium ATPase 2a (SERCA2a), a key regulator of the excitation-contraction coupling, to maintain calcium homeostasis, and PKM2 deficiency exacerbated LPS-induced cardiac systolic dysfunction by impairing SERCA2a expression. In conclusion, these findings highlight that PKM2 plays an essential role in gram-negative sepsis-induced cardiomyopathy, which provides an attractive target for the prevention and treatment of septic cardiomyopathy.
- 23 December 2022
- Published by Springer Nature in Cell Death Discovery
- Vol. 8 (1) , 1-14
Open AccessPKM2 deficiency exacerbates gram-negative sepsis-induced cardiomyopathy via disrupting cardiac calcium homeostasis
Sepsis is a life-threatening syndrome with multi-organ dysfunction in critical care medicine. With the occurrence of sepsis-induced cardiomyopathy (SIC), characterized by reduced ventricular contractility, the mortality of sepsis is boosted to 70–90%. Pyruvate kinase M2 (PKM2) functions in a variety of biological processes and diseases other than glycolysis, and has been documented as a cardioprotective factor in several heart diseases. It is currently unknown whether PKM2 influences the development of SIC. Here, we found that PKM2 was upregulated in cardiomyocytes treated with LPS both in vitro and in vivo. Pkm2 inhibition exacerbated the LPS-induced cardiac damage to neonatal rat cardiomyocytes (NRCMs). Furthermore, cardiomyocytes lacking PKM2 aggravated LPS-induced cardiomyopathy, including myocardial damage and impaired contractility, whereas PKM2 overexpression and activation mitigated SIC. Mechanism investigation revealed that PKM2 interacted with sarcoplasmic/endoplasmic reticulum calcium ATPase 2a (SERCA2a), a key regulator of the excitation-contraction coupling, to maintain calcium homeostasis, and PKM2 deficiency exacerbated LPS-induced cardiac systolic dysfunction by impairing SERCA2a expression. In conclusion, these findings highlight that PKM2 plays an essential role in gram-negative sepsis-induced cardiomyopathy, which provides an attractive target for the prevention and treatment of septic cardiomyopathy.
- Open Access
- 7 June 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (11) , e024854
Pyruvate Kinase M2 Protects Heart from Pressure Overload‐Induced Heart Failure by Phosphorylating RAC1
Background: Heart failure, caused by sustained pressure overload, remains a major public health problem. PKM (pyruvate kinase M) acts as a rate‐limiting enzyme of glycolysis. PKM2 (pyruvate kinase M2), an alternative splicing product of PKM, plays complex roles in various biological processes and diseases. However, the role of PKM2 in the development of heart failure remains unknown. Methods and Results: Cardiomyocyte‐specific Pkm2 knockout mice were generated by crossing the floxed Pkm2 mice with α‐MHC (myosin heavy chain)‐Cre transgenic mice, and cardiac specific Pkm2 overexpression mice were established by injecting adeno‐associated virus serotype 9 system. The results showed that cardiomyocyte‐specific Pkm2 deletion resulted in significant deterioration of cardiac functions under pressure overload, whereas Pkm2 overexpression mitigated transverse aortic constriction‐induced cardiac hypertrophy and improved heart functions. Mechanistically, we demonstrated that PKM2 acted as a protein kinase rather than a pyruvate kinase, which inhibited the activation of RAC1 (rho family, small GTP binding protein)‐MAPK (mitogen‐activated protein kinase) signaling pathway by phosphorylating RAC1 in the progress of heart failure. In addition, blockade of RAC1 through NSC23766, a specific RAC1 inhibitor, attenuated pathological cardiac remodeling in Pkm2 deficiency mice subjected to transverse aortic constriction. Conclusions: This study revealed that PKM2 attenuated overload‐induced pathological cardiac hypertrophy and heart failure, which provides an attractive target for the prevention and treatment of cardiomyopathies.
- 7 June 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (11) , e024854
Open AccessPyruvate Kinase M2 Protects Heart from Pressure Overload‐Induced Heart Failure by Phosphorylating RAC1
Background: Heart failure, caused by sustained pressure overload, remains a major public health problem. PKM (pyruvate kinase M) acts as a rate‐limiting enzyme of glycolysis. PKM2 (pyruvate kinase M2), an alternative splicing product of PKM, plays complex roles in various biological processes and diseases. However, the role of PKM2 in the development of heart failure remains unknown. Methods and Results: Cardiomyocyte‐specific Pkm2 knockout mice were generated by crossing the floxed Pkm2 mice with α‐MHC (myosin heavy chain)‐Cre transgenic mice, and cardiac specific Pkm2 overexpression mice were established by injecting adeno‐associated virus serotype 9 system. The results showed that cardiomyocyte‐specific Pkm2 deletion resulted in significant deterioration of cardiac functions under pressure overload, whereas Pkm2 overexpression mitigated transverse aortic constriction‐induced cardiac hypertrophy and improved heart functions. Mechanistically, we demonstrated that PKM2 acted as a protein kinase rather than a pyruvate kinase, which inhibited the activation of RAC1 (rho family, small GTP binding protein)‐MAPK (mitogen‐activated protein kinase) signaling pathway by phosphorylating RAC1 in the progress of heart failure. In addition, blockade of RAC1 through NSC23766, a specific RAC1 inhibitor, attenuated pathological cardiac remodeling in Pkm2 deficiency mice subjected to transverse aortic constriction. Conclusions: This study revealed that PKM2 attenuated overload‐induced pathological cardiac hypertrophy and heart failure, which provides an attractive target for the prevention and treatment of cardiomyopathies.
- 1 July 2021
- Published by Elsevier in Pharmacological Research
- Vol. 169, 105642
SNX17 protects the heart from doxorubicin-induced cardiotoxicity by modulating LMOD2 degradation
- 1 July 2021
- Published by Elsevier in Pharmacological Research
- Vol. 169, 105642
SNX17 protects the heart from doxorubicin-induced cardiotoxicity by modulating LMOD2 degradation
- Open Access
- 30 November 2020
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 7
The Regulatory Role of Histone Modification on Gene Expression in the Early Stage of Myocardial Infarction
Myocardial infarction (MI) is a fatal heart disease with high morbidity and mortality. Various studies have demonstrated that a series of relatively specific biological events occur within 24 h of MI. However, the roles of histone modifications in this pathological process are still poorly understood. To investigate the regulation of histone modifications on gene expression in early MI, we performed RNA sequencing (RNA-seq) and chromatin immunoprecipitation sequencing (ChIP-seq) on myocardial tissues 24 h after the onset of MI. The genome-wide profiles of five histone marks (H3K27ac, H3K9ac, H3K4me3, H3K9me3, and H3K27me3) were explored through ChIP-seq. RNA-seq identified 1,032 differentially expressed genes (DEGs) between the MI and sham groups. ChIP-seq analysis found that 195 upregulated DEGs were modified by change of at least one of the three active histone marks (H3K27ac, H3K9ac, and H3K4me3), and the biological processes and pathways analysis showed that these DEGs were significantly enriched in cardiomyocyte differentiation and development, inflammation, angiogenesis, and metabolism. In the transcriptional regulatory network, Ets1, Etv1, and Etv2 were predicted to be involved in gene expression regulation. In addition, by integrating super-enhancers (SEs) with RNA-seq data, 76 DEGs were associated with H3K27ac-enriched SEs in the MI group, and the functions of these SE-associated DEGs were mainly related to angiogenesis. Our results suggest that histone modifications may play important roles in the regulation of gene expression in the early stage of MI, and the early angiogenesis response may be initiated by SEs.
- 30 November 2020
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 7
Open AccessThe Regulatory Role of Histone Modification on Gene Expression in the Early Stage of Myocardial Infarction
Myocardial infarction (MI) is a fatal heart disease with high morbidity and mortality. Various studies have demonstrated that a series of relatively specific biological events occur within 24 h of MI. However, the roles of histone modifications in this pathological process are still poorly understood. To investigate the regulation of histone modifications on gene expression in early MI, we performed RNA sequencing (RNA-seq) and chromatin immunoprecipitation sequencing (ChIP-seq) on myocardial tissues 24 h after the onset of MI. The genome-wide profiles of five histone marks (H3K27ac, H3K9ac, H3K4me3, H3K9me3, and H3K27me3) were explored through ChIP-seq. RNA-seq identified 1,032 differentially expressed genes (DEGs) between the MI and sham groups. ChIP-seq analysis found that 195 upregulated DEGs were modified by change of at least one of the three active histone marks (H3K27ac, H3K9ac, and H3K4me3), and the biological processes and pathways analysis showed that these DEGs were significantly enriched in cardiomyocyte differentiation and development, inflammation, angiogenesis, and metabolism. In the transcriptional regulatory network, Ets1, Etv1, and Etv2 were predicted to be involved in gene expression regulation. In addition, by integrating super-enhancers (SEs) with RNA-seq data, 76 DEGs were associated with H3K27ac-enriched SEs in the MI group, and the functions of these SE-associated DEGs were mainly related to angiogenesis. Our results suggest that histone modifications may play important roles in the regulation of gene expression in the early stage of MI, and the early angiogenesis response may be initiated by SEs.